A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation.

导出 LinkOut

翻译打印收藏纠错

作者： Antonio,Matrone ^[1] ; Alessandro,Brancatella ^[1] ; Piero,Marchetti ^[2] ; Enrico,Vasile ^[3] ; Ugo,Boggi ^[4] ; Rossella,Elisei ^[1] ; Filomena,Cetani ^[5] ; Claudio,Marcocci ^[5] ; Paolo,Vitti ^[1] ; Francesco,Latrofa ^[1]

作者单位： Department of Clinical and Experimental Medicine, Unit of Endocrinology I, University of Pisa, I-56124 Pisa, Italy. ^[1] Department of Clinical and Experimental Medicine, Division of Metabolism and Cell Transplantation, University of Pisa, I-56124 Pisa, Italy. ^[2] Department of Translational Research and of New Surgical and Medical Technologies, Unit of Oncology, University of Pisa, I-56124 Pisa, Italy. ^[3] Department of Translational Research and of New Surgical and Medical Technologies, Division of General and Transplant Surgery, University of Pisa, I-56124 Pisa, Italy. ^[4] Department of Clinical and Experimental Medicine, Unit of Endocrinology II, University of Pisa, I-56124 Pisa, Italy. ^[5]

关键词 MEN1 alport syndrome cancer recurrence glucagon hyperparathyroidism neuroendocrine tumor transplantation

DOI 10.3892/mco.2017.1542

PMID 29468058

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Molecular and clinical oncology

2018年8卷3期

449-452页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation.

Molecular and clinical oncology

相似文献

Molecular and clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation.

Molecular and clinical oncology

相似文献

Molecular and clinical oncology

相关期刊

检索历史清除